Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helena Katchman

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 20, 2022
The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patientsEsther Saiag, Ayelet Grupper, Irit Avivi, et al.
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.
Transplantation Proceedings|March 29, 2022
Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant RecipientsAyelet Grupper, Liane Rabinowich, Merav Ben-Yehoyada, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 13, 2009
Embryonic pig pancreatic tissue for the treatment of diabetes in a nonhuman primate modelGil Hecht, Smadar Eventov-Friedman, Chava Rosen, et al.
Antiviral Therapy|March 19, 2019
High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life dataYael Gozlan, Efrat Bucris, Rachel Shirazi, et al.
Nature Medicine|June 21, 2022
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a studyStephen A Harrison, Federico Perez Manghi, William B Smith, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 20, 2022
The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patientsEsther Saiag, Ayelet Grupper, Irit Avivi, et al.
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.
Transplantation Proceedings|March 29, 2022
Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant RecipientsAyelet Grupper, Liane Rabinowich, Merav Ben-Yehoyada, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 13, 2009
Embryonic pig pancreatic tissue for the treatment of diabetes in a nonhuman primate modelGil Hecht, Smadar Eventov-Friedman, Chava Rosen, et al.
Antiviral Therapy|March 19, 2019
High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life dataYael Gozlan, Efrat Bucris, Rachel Shirazi, et al.
Nature Medicine|June 21, 2022
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a studyStephen A Harrison, Federico Perez Manghi, William B Smith, et al.
Pageof 4